Clinical observation of recombinant human interferon α2β suppository in the treatment of HPV infection
Objective To analyze the clinical efficacy of recombinant human interferon alpha 2 beta suppository in the treatment of HPV infection. Methods 100 cases of hospital diagnosis and treatment of laboratory diagnosis of HPV infection from January 2015 to December 2016 were randomly divided into observation group and control group according to the digital table method, each group 50 cases. The observation group was treated with recombinant human interferon alpha 2 beta suppository treatment, control group with treatment of Policresulen Vaginal Suppository. The clinical efficacy of the two groups was compared and the changes of viral load before and after treatment were compared between the two groups. Meanwhile, the incidence of adverse reactions in the two groups during the treatment period was recorded. Results The effective rate of the observation group was significantly higher than the control group (P<0.05); two groups of patients before and after treatment of viral load differences were statistically significant (P<0.05), the observation group decreased viral load was significantly higher than the control group (P<0.05); during the two groups of patients had no obvious adverse reaction. Conclusion Recombinant human interferon alpha 2 beta suppository has good clinical efficacy in HPV infection, the virus can effectively improve the removal efficiency and reduce viral load, and high safety, is worthy of clinical application.
recombinant human interferon α2β suppositoryHPV infectionclinical efficacy
NETL
NSTL
万方数据
维普
